A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-Acting reversible contraceptives

Human Reproduction

Volumn 29, Issue 7, 2014, Pages 1393-1399

  Modesto, Waleska ^a   Bahamondes, M Valeria ^a   Bahamondes, Luis ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

copper intrauterine device; counseling; implant; levonorgestrel releasing intrauterine system; long Acting contraceptive methods

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; ETONOGESTREL; LEVONORGESTREL; LONG ACTING DRUG; LONG ACTING REVERSIBLE CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG; DESOGESTREL;

ADULT; ARTICLE; BLEEDING DISORDER; CONTRACEPTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMPLANT DELIVERY DEVICE; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE DEVICE EXPULSION; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; MEDICAL DEVICE COMPLICATION; MENSTRUATION DISORDER; PAIN; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN; ADVERSE EFFECTS; BLEEDING; BODY MASS; COPPER INTRAUTERINE DEVICE; COUNSELING; DRUG EFFECTS; MENSTRUATION; PROCEDURES; UTILIZATION;

ADULT; BODY MASS INDEX; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; COUNSELING; DESOGESTREL; FEMALE; HEMORRHAGE; HUMANS; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENSTRUATION; WEIGHT GAIN;

EID: 84902690131     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu089     Document Type: Article

References (27)

1. Agrawal A, Robinson C. An assessment of the first 3 years use of Implanon in Luton. J Fam Plann Reprod Health Care 2005;31:310-312.
2. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copperreleasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
3. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608-613.
4. Bahamondes MV, de Lima Y, Teich V, Bahamondes L, Monteiro I. Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil. Contraception 2012;86:244-250.
5. Baldaszti E, Wimmer-Puchinger B, Löschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 2003;67:87-91.
6. Bitzer J, Cupanik V, Fait T, Gemzell-Danielsson K, Grob P, Oddens BJ, Pawelczyk L, Unzeitig V. Factors influencing womens selection of combined hormonal contraceptive methods after counselling in 11 countries: results from a subanalysis of the CHOICE study. Eur J Contracept Reprod Health Care 2013;18:372-380.
7. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5:21-28.
8. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 2002;65:21-27.
9. Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 1999; 14:976-981.
10. Davie JE,Walling MR, Mansour DJ, Bromham D, Kishen M, Fowler P. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 1996;18:150-159.
11. Diaz J, Bahamondes L, Monteiro I, Petta C, Hildalgo MM, Arce XE. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception 2000;62:59-61.
12. Ferreira JM, Nunes FR, ModestoW, GonçalvesMP, Bahamondes L. Reasons for Brazilian women to switch from different contraceptives to long-Acting reversible contraceptives. Contraception 2014;89:17-21.
13. Gemzell-Danielsson K, Thunell L, Lindeberg M, Tydén T, Marintcheva-Petrova M, Oddens BJ. Comprehensive counseling about combined hormonal contraceptives changes the choice of contraceptive methods: results of the CHOICE program in Sweden. Acta Obstet Gynecol Scand 2011;90:869-877.
14. HarveyC, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception 2009;80:527-532.
15. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129-132.
16. Kalmuss D, Davidson AR, Cushman LF, Heartwell S, Rulin M. Determinants of early implant discontinuation among low-income women. Fam Plann Perspect 1996;28:256-260.
17. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception 2006;74: 287-289.
18. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011;83:202-210.
19. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, Secura G. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117:1105-1113.
20. Peterson HB, Curtis KM. Clinical practice. Long-Acting methods of contraception. N Engl J Med 2005;353:2169-2175.
21. Rubenstein J, Rubenstein P, Barter J, Pittrof R. Counselling styles and their effect on subdermal contraceptive implant continuation rates. Eur J Contracept Reprod Health Care 2011;16:225-228.
22. Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009;79:189-193.
23. Smith A, Reuter S. An assessment of the use of Implanon in three community services. J Fam Plann Reprod Health Care 2002;28:193-196.
24. Suhonen S, Haukkamaa M, JakobssonT, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004; 69:407-412.
25. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, SecuraGM. Effectiveness of long-Acting reversible contraception. N Engl J Med 2012; 366:1998-2007.
26. Wong RC, Bell RJ, Thunuguntla K, McNamee K, Vollenhoven B. Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. Contraception 2009;80:452-456.
27. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation. A multicentred Phase III comparative study of two hormonal contraceptive preparations given once-A-month by intramuscular injection. II. The comparison of bleeding patterns. Contraception 1989;40:531-551.